Early detection of clinically localized PCa is the most efficient approach to reduce unnecessary treatments and decrease deaths, and serum prostate specific antigen (PSA)-based testing has been widely used in the last decades for PCa detection. The gene discussed is KLK3; the disease is posterior cortical atrophy.